Xeris Biopharma Holdings reported third-quarter total revenue of $107.2 million, a 44% increase from the prior year, driven by a 93% surge in Recorlev net revenue to $71.5 million. The company raised its full-year 2026 total revenue guidance to $395–$405 million and increased its 2030 outlook to more than $1 billion. Net income for the quarter was $11.3 million, compared to $0.6 million in the same period last year. Additionally, Xeris announced that Menassie M. Taddese joined the board of directors effective November 2, 2026. The company operates as a biopharmaceutical firm focused on endocrine and rare diseases.
